<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/446652#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1F10(?-152) binds IL1RAPL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK8 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1F10 is cleaved</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1F10 binds IL1RL2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP1,2 binds p-NFkB p105:TPL2:ABIN2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1R1:IL1:IL1RAP:MYD88 homodimer binds IRAK4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 receptor type 1: Interleukin 1 binds Interleukin-1 receptor accessory protein, membrane associated isoform</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBA is phosphorylated by Phospho IKKB kinase</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPL2 phosphorylates MEK1, SEK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF betaTrCP ubiquitinates NFKB p105 within p-S927, S932-NFkB p105:TPL2:ABIN2 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates NFkB p105 within the NFkB p105:TPL2:ABIN2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 induces oligomerisation of TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1 receptor antagonist protein binds Interleukin 1 receptors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Expression of IL18, ALOX5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL18:IL18R1 binds IL18RAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL18BP binds IL18</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1B,Myr82K-Myr83K-IL1A:IL1R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1F10 binds IL1RAPL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL18 binds IL18R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB p105, TPL2 (COT) and ABIN2 form a stable complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB phosphorylates TPL2 (MAP3K8) at Ser400</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3xUb,p-S-NFkB p105:TPL2:ABIN2 dissociates due to degradation of p105</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-38 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukins are immunomodulatory proteins that elicit a wide array of responses in cells and tissues. Interleukin 1 family member 10 (IL1F10, IL 38) is a member of the IL1 family (Lin et al. 2001, Bensen et al. 2001). IL1F10 is selectively produced by human apoptotic cells (Mora et al. 2016) and human epidermal keratinocytes (based on mRNA studies) (Boutet M A et al. 2016). IL1F10 can bind to interleukin 1 receptor like 2 (IL1RL2) and may result in the suppression of IL 17 and IL 22 and induction of IL 6 production (van de Veerdonk et al. 2012, Mora et al. 2016). IL1F10 is synthesized as precursors that require N terminal processing to attain full receptor agonist or antagonist function (Mora et al. 2016). Both full length (1 &#8211; 152 amino acids) and N terminal truncated (20 &#8211; 152 amino acids) IL1F10 can bind Interleukin 1 receptor accessory protein like 1 (IL1RAPL1) (Mora et al. 2016). The binding affinity of truncated IL1F10 is much higher than that of the full length.  However, binding of the full length or truncated forms has distinct outcomes; the former induces IL6 and the latter suppresses IL6 via JNK and AP1 signaling (Mora et al. 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-18 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-18 (IL18, pro-IL18) is a pleiotropic and pro inflammatory cytokine. It belongs to the Interleukin-1 (IL1 superfamily (Alboni et al. 2010, Krumm et al. 2017, Dinarello 1999). IL18 is synthesized as an inactive 24-kDa precursor protein that is cleaved by extracellular proteases such as caspase-1, protease 3, serine protease, elastase or cathepsin G (Fantuzzi    Dinarello 1999, Gracie et al. 2004, Sugawara et al. 2001), forming an 18-kDa mature protein (Arend et al. 2008, Akita et al. 1997, Fantuzzi et al. 1998, Ghayur et al. 1997, Gu et al. 1997, Ushio et al. 1996).  IL18 also occurs as a short isoform, the result of an alternative splicing event that removes 57 bp/19 aa (IL18alpha) (Conti et al. 1997, Yang et al. 2005). This short isoform has a modest synergistic action with the IL18 canonical active form. The IL18 receptor (IL18R) belongs to the Interleukin-1 receptor/Toll like receptor superfamily. It consists of two subunits, Interleukin-18 receptor 1 (IL18R1, IL-18R&#945;, IL1Rrp1, IL18R1, IL-1R5) and Interleukin-18 receptor accessory protein (IL18RAP, IL18RB, IL-18R&#946;,IL-18RacP, IL-18RII or IL-1R7). Both subunits have three extracellular immunoglobulin-like domains and one intracellular Toll/IL-1 receptor (TIR) domain (O&apos;Neill    Dinarello 2000, Sims 2002). It is believed that IL18 binds first to IL18R1 and later recruits IL18RAP to form a high-affinity heterotrimeric complex (Sims 2002, Sergi    Pentilla 2004, Alboni et al. 2009).  A short isoform of IL18R1 lacks the TIR domain (IL18R1 type II) (Alboni et al. 2009), which is required for signaling, leading to the suggestion that IL18R1 type II is a decoy receptor (Colotta et al. 1994). A truncated form of IL18RAP containing only one of the three immunoglobulin domains stabilizes IL18 binding to IL18R1 but prevents signaling. IL-18 binding protein (IL18BP), a 38-kDa soluble protein, is another negative regulator of IL18 signaling. It has some sequence homology with IL18R1 (Im et al. 2002 , Kim et al. 2002, Novick et al. 1999). IL18BP binds with high affinity to mature IL18, preventing its interaction with IL18R1. Several isoforms IL18BP have been described (Kim et al. 2000). Interleukin-37 (IL37, IL-1F7), another negative regulator of IL18 signaling, is able to bind IL18BP and IL18RAP preventing signaling (Bufler et al.2002, Pan et al. 2001, Kumar et al. 2002). IL18 stimulates Interferon gamma (IFNG, IFN-&#947;) production from T-helper lymphocytes cells (Th1) and macrophages and enhances the cytotoxicity of natural killer (NK) cells. IL18 stimulated IFNG production is synergistically amplified by other Th1-related cytokines such as IL2, IL15, IL12 and IL23 (Boraschi    Dinarello 2006, Park et al. 2007, Dinarello 2007, Dinarello    Fantuzzi 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37(1-?) and IL37 (?-) dissocates from IL37(1-?):IL37(?-218):CASP1(120-197):CASP1(317-404)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37(?-218) binds SMAD3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37(?-218) binds p-S423,S425-SMAD3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37 binds 2x(CASP1(120-197):CASP1(317-404))</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPNs gene transcription and translation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37, IL37(?-218) translocates from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL33 binds IL1RL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL33:IL1RL1 binds IL1RAP-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The IL-1 family of cytokines that interact with the Type 1 IL-1R include IL-1&#945; (IL1A), IL-1&#946; (IL1B) and the IL-1 receptor antagonist protein (IL1RAP). IL1RAP is synthesized with a signal peptide and secreted as a mature protein via the classical secretory pathway.  IL1A and IL1B are synthesised as cytoplasmic precursors (pro-IL1A and pro-IL1B) in activated cells. They have no signal sequence, precluding secretion via the classical ER-Golgi route (Rubartelli et al. 1990). Processing of pro-IL1B to the active form requires caspase-1 (Thornberry et al. 1992), which is itself activated by a molecular scaffold termed the inflammasome (Martinon et al. 2002). Processing and release of IL1B are thought to be closely linked, because mature IL1B is only seen inside inflammatory cells just prior to release (Brough et al. 2003). It has been reported that in monocytes a fraction of cellular IL1B is released by the regulated secretion of late endosomes and early lysosomes, and that this may represent a cellular compartment where caspase-1 processing of pro-IL1B takes place (Andrei et al. 1999). Shedding of microvesicles from the plasma membrane has also been proposed as a mechanism of secretion (MacKenzie et al. 2001). These proposals superceded previous models in which non-specific release due to cell lysis and passage through a plasma membrane pore were considered. However, there is evidence in the literature that supports all of these mechanisms and there is still controversy over how IL1B exits from cells (Brough    Rothwell 2007). A calpain-like potease has been reported to be important for the processing of  pro-IL1A, but much less is known about how IL1A is released from cells and what specific roles it plays in biology.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin 1 (IL1) signals via Interleukin 1 receptor 1 (IL1R1), the only signaling-capable IL1 receptor. This is a single chain type 1 transmembrane protein comprising an extracellular ligand binding domain and an intracellular  region called the Toll/Interleukin-1 receptor (TIR) domain that is structurally conserved and shared by other members of the two families of receptors (Xu et al. 2000). This domain is also shared by the downstream adapter molecule MyD88. IL1 binding to IL1R1 leads to the recruitment of a second receptor chain termed the IL1 receptor accessory protein (IL1RAP or IL1RAcP) enabling the formation of a high-affinity ligand-receptor complex that is capable of signal transduction. Intracellular signaling is initiated by the recruitment of MyD88 to the IL-1R1/IL1RAP complex. IL1RAP is only recruited to IL1R1 when IL1 is present; it is believed that a TIR domain signaling complex is formed between the receptor and the adapter TIR domains. The recruitment of MyD88 leads to the recruitment of Interleukin-1 receptor-associated kinase (IRAK)-1 and -4, probably via their death domains. IRAK4 then activates IRAK1, allowing IRAK1 to autophosphorylate. Both IRAK1 and IRAK4 then dissociate from MyD88 (Brikos et al. 2007) which remains stably complexed with IL-1R1 and IL1RAP. They in turn interact with Tumor Necrosis Factor Receptor (TNFR)-Associated Factor 6 (TRAF6), which is an E3 ubiquitin ligase (Deng et al. 2000). TRAF6 is then thought to auto-ubiquinate, attaching K63-polyubiquitin to itself with the assistance of the E2 conjugating complex Ubc13/Uev1a. K63-pUb-TRAF6 recruits Transforming Growth Factor (TGF) beta-activated protein kinase 1 (TAK1) in a complex with TAK1-binding protein 2 (TAB2) and TAB3, which both contain nuclear zinc finger motifs that interact with K63-polyubiquitin chains (Ninomiya-Tsuji et al. 1999). This activates TAK1, which then activates  inhibitor of NF-kappaB (IkappaB) kinase 2 (IKK2 or IKKB) within the IKK complex, the kinase responsible for phosphorylation of IkappaB. The IKK complex also contains the scaffold protein NF-kappa B essential modulator (NEMO). TAK1 also couples to the upstream kinases for p38 and c-jun N-terminal kinase (JNK). IRAK1 undergoes K63-linked polyubiquination; Pellino E3 ligases are important in this process. (Butler et al. 2007; Ordureau et al. 2008). The activity of these proteins is greatly enhanced by IRAK phosphorylation (Schauvliege et al. 2006), leading to K63-linked polyubiquitination of IRAK1. This recruits NEMO to IRAK1, with NEMO binding to polyubiquitin (Conze et al. 2008).  TAK1 activates IKKB (and IKK), resulting in phosphorylation of the inhibitory IkB proteins and enabling translocation of NFkB to the nucleus; IKKB also phosphorylates NFkB p105, leading to its degradation and the subsequent release of active TPL2 that triggers the extracellular-signal regulated kinase (ERK)1/2 MAPK cascade. TAK1 can also trigger the p38 and JNK MAPK pathways via activating the upstream MKKs3, 4 and 6. The MAPK pathways activate a number of downstream kinases and transcription factors that co-operate with NFkB to induce the expression of a range of TLR/IL-1R-responsive genes. There are reports suggesting that IL1 stimulation increases nuclear localization of IRAK1 (Bol et al. 2000) and that nuclear IRAK1 binds to the promoter of NFkB-regulated gene and IkBa, enhancing binding of the NFkB p65 subunit to NFkB responsive elements within the IkBa promoter.  IRAK1 is required for IL1-induced Ser-10 phosphorylation of histone H3 in vivo (Liu et al. 2008). However, details of this aspect of IRAK1 signaling mechanisms remain unclear. Interleukin-18 is another Interleukin-1 related cytokine which signals through IL18R and IL18RAP subunit receptors (which share homology with IL1R and IL1RAP in the cytokine signaling cascade). Later it follows a MYD88/IRAK1/TRAF6 cascade signaling until reach the NFKB activation (Moller et al. 2002). Interleukin 33, 36, 37 and 38 are relatively recently discovered Interleukin-1 related citokines which are also able to signal through IL1 receptor subunits or other as IL18R, IL37R (Schmitz et al. 2005, Yi et al. 2016, Lunding et al. 2015, van de Veendorck et al. 2012, Lin et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-37 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukins (IL) are immunomodulatory proteins that elicit a wide array of responses in cells and tissues. Interleukin 37 (IL37), also known as IL 1F7, is a member of the IL 1 family (Sharma et al. 2008). Isoform b of IL37 (referred just as IL37) is synthesized as a precursor that requires processing (primarily by caspase 1) to attain full receptor agonist or antagonist function (Kumar et al. 2002). Both full length and processed IL37 can bind to the IL 18 binding protein (IL 18BP) and the Interleukin 18 receptor 1 (IL 18R1) (Shi et al. 2003). Upon binding to the IL18R1, IL37 recruits Single Ig IL 1 related receptor (SIGIRR) (Nold-Petry et al. 2015). The IL37:IL18R1 complex can activate phosphorylation of Signal transducer and activator of transcription 3 (STAT3), Tyrosine protein kinase Mer and Phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN and can also inhibit Nuclear factor NF kappa B p105 subunit (NFKB) (Nold-Petry et al. 2015). Processed IL37 can be secreted from the cytosol to the extracellular space or translocated into the nucleus (Bulau et al. 2014). Full length IL37 can also be secreted from the cytosol to the extracellular space (Bulau et al. 2014). Processed IL37 can bind with Mothers against decapentaplegic homolog 3 (SMAD3) in the cytosol and then translocate to the nucleus, where it facilitates transcription of Tyrosine protein phosphatase non receptors (PTPNs) (Nold et al. 2010, Luo et al. 2017). These events ultimately lead to suppression of cytokine production in several types of immune cells resulting in reduced inflammation.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-36 pathway</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-36 alpha (IL36A), IL36B and IL36G are collectively known as IL36. They are members of the Interlukin-1 family that signal through a receptor composed of Interleukin-1 receptor-like 2 (IL1RL2, IL36R) and Interleukin-1 receptor accessory protein (IL1RAP,  IL-1R/AcP)  to promote inflammatory responses. Interleukin-36 receptor antagonist protein (IL36RN, IL36Ra) is a natural antagonist. IL36 is expressed predominantly by epithelial cells and is implicated strongly through functional and genetic evidence in the pathology of psoriatic disorders.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP3K8 (TPL2)-dependent MAPK1/3 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tumor progression locus-2 (TPL2, also known as COT and MAP3K8) functions as a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) in various stress-responsive signaling cascades. MAP3K8 (TPL2) mediates phosphorylation of MAP2Ks (MEK1/2) which in turn phosphorylate MAPK (ERK1/2) (Gantke T et al., 2011). In the absence of extra-cellular signals, cytosolic MAP3K8 (TPL2) is held inactive in the complex with ABIN2 (TNIP2) and NFkB p105 (NFKB1) (Beinke S et al., 2003; Waterfield MR et al., 2003; Lang V et al., 2004). This interaction stabilizes MAP3K8 (TPL2) but also prevents MAP3K8 and NFkB from activating their downstream signaling cascades by inhibiting the kinase activity of MAP3K8 and the proteolysis of NFkB precursor protein p105. Upon activation of MAP3K8 by various stimuli (such as LPS, TNF-alpha, and IL-1 beta), IKBKB phosphorylates NFkB p105 (NFKB1) at Ser927 and Ser932, which trigger p105 proteasomal degradation and releases MAP3K8 from the complex (Beinke S et al., 2003, 2004; Roget K et al., 2012). Simultaneously, MAP3K8 is activated by auto- and/or transphosphorylation (Gantke T et al. 2011; Yang HT et al. 2012). The released active MAP3K8 phosphorylates its substrates, MAP2Ks. The free MAP3K8, however, is also unstable and is targeted for proteasome-mediated degradation, thus restricting prolonged activation of MAP3K8 (TPL2) and its downstream signaling pathways (Waterfield MR et al. 2003; Cho J et al., 2005). Furthermore, partially degraded NFkB p105 (NFKB1) into p50 can dimerize with other NFkB family members to regulate the transcription of target genes. MAP3K8 activity is thought to regulate the dynamics of transcription factors that control an expression of diverse genes involved in growth, differentiation, and inflammation. Suppressing the MAP3K8 kinase activity with selective inhibitors, such as C8-chloronaphthyridine-3-carbonitrile, caused a significant reduction in TNFalpha production in LPS- and IL-1beta-induced both primary human monocytes and human blood (Hall JP et al. 2007). Similar results have been reported for mouse LPS-stimulated RAW264.7 cells (Hirata K et al. 2010). Moreover, LPS-stimulated macrophages derived from Map3k8 knockout mice secreted lower levels of pro-inflammatory cytokines such as TNFalpha, Cox2, Pge2 and CXCL1 (Dumitru CD et al. 2000; Eliopoulos AG et al. 2002). Additionally, bone marrow-derived dendritic cells (BMDCs) and macrophages from Map3k8 knockout mice showed significantly lower expression of IL-1beta in response to LPS, poly IC and LPS/MDP (Mielke et al., 2009). However, several other studies seem to contradict these findings and Map3k8 deficiency in mice has been also reported to enhance pro-inflammatory profiles. Map3k8 deficiency in LPS-stimulated macrophages was associated with an increase in nitric oxide synthase 2 (NOS2) expression (L&#243;pez-Pel&#225;ez et al., 2011). Similarly, expression of IRAK-M, whose function is to compete with IL-1R-associated kinase (IRAK) family of kinases, was decreased in Map3k8-/- macrophages while levels of TNF and IL6 were elevated (Zacharioudaki et al., 2009). Moreover, significantly higher inflammation level was observed in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Map3k8-/- mouse skin compared to WT skin (DeCicco-Skinner K. et al., 2011). Additionally, MAP3K8 activity is associated with NFkB inflammatory pathway. High levels of active p65 NFkB were observed in the nucleus of Map3k8 -/- mouse keratinocytes that dramatically increased within 15-30 minutes of TPA treatment. Similarly, increased p65 NFkB was observed in Map3k8-deficient BMDC both basally and after stimulation with LPS when compared to wild type controls (Mielke et al., 2009). The data opposes the findings that Map3k8-deficient mouse embryo fibroblasts and human Jurkat T cells with kinase domain-deficient protein have a reduction in NFkB activation but only when certain stimuli are administered (Lin et al., 1999; Das S et al., 2005). Thus, it is possible that whether MAP3K8 serves more of a pro-inflammatory or anti-inflammatory role may depend on cell- or tissue type and on stimuli (LPS vs. TPA, etc.) (Mielke et al., 2009; DeCicco-Skinner K. et al., 2012). MAP3K8 has been also studied in the context of carcinogenesis, however the physiological role of MAP3K8 in the etiology of human cancers is also convoluted (Vougioukalaki M et al., 2011; DeCicco-Skinner K. et al., 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1-dependent IKK and NF-kappa-B activation  </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B is sequestered in the cytoplasm in a complex with inhibitor of NF-kappa-B (IkB). Almost all NF-kappa-B activation pathways are mediated by IkB kinase (IKK), which phosphorylates IkB resulting in dissociation of NF-kappa-B from the complex. This allows translocation of NF-kappa-B to the nucleus where it regulates gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of NF-kappa B signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear factor kappa B (NF-kappa-B, NF-&#954;B) is activated by a diverse range of stimuli including cytokines, ligands of pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) in myeloid cells, antigen-activated TCR in T-cells and by DNA damage (reviewed in Yu H et al. 2020; Zhang T et al. 2021). NF-kappa-B regulates the transcription of genes that are involved in immune and inflammatory responses, cell cycle, cell proliferation and apoptosis (Bhatt D    Ghosh S 2014; Liu T et al. 2017; Yu H et al. 2020). In unstimulated cells, NF-&#954;B is sequestered in the cytosol through interactions with a class of inhibitor proteins, called NF-&#954;B inhibitors (IkBs, such as NFKBIA or NFKBIB) (Jacobs MD    Harrison SC 1998). IkBs mask the nuclear localization signal (NLS) of NF-&#954;B preventing its nuclear translocation (Cervantes CF et al. 2011). A key event in NF-&#954;B activation involves phosphorylation of IkBs by the I&#954;B kinase (IKK) complex which consists of CHUK, IKBKB and IKBKG subunits (Isra&#235;l A 2010). The activated NF-&#954;B signaling is tightly controlled at multiple levels (Dorrington MG    Fraser IDC 2019; Prescott JA et al. 2021). Dysregulated NF-&#954;B activity can cause tissue damage associated with inflammatory diseases and is also linked to tumorigenesis (Aggarwal BB    Sung B 2011; Liu T et al.2017; Barnabei L et al. 2021). The regulation of NF-&#954;B is cell-type-, context- , and stimulus-dependent and is crucial for orchestrating specific cellular responses (Mussbacher M et al. 2019). This Reactome module describes several molecular mechanisms that regulate TLR-mediated NF-&#954;B signaling at the level of the IKK signaling complex.   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 family signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Interleukin-1 (IL1) family of cytokines comprises 11 members, namely Interleukin-1 alpha (IL1A), Interleukin-1 beta (IL1B), Interleukin-1 receptor antagonist protein (IL1RN, IL1RA), Interleukin-18 (IL18), Interleukin-33 (IL33), Interleukin-36 receptor antagonist protein (IL36RN, IL36RA), Interleukin-36 alpha (IL36A), Interleukin-36 beta (IL36B), Interleukin-36 gamma (IL36G), Interleukin-37 (IL37) and Interleukin-38 (IL38). The genes encoding all except IL18 and IL33 are on chromosome 2. They share a common C-terminal three-dimensional structure and  with apart from  IL1RN they are synthesized without a hydrophobic leader sequence and are not secreted via the classical reticulum endoplasmic-Golgi pathway. IL1B and IL18, are produced as biologically inactive propeptides that are cleaved to produce the mature, active interleukin peptide. The IL1 receptor (IL1R) family comprises 10 members: Interleukin-1 receptor type 1 (IL1R1, IL1RA), Interleukin-1 receptor type 2 (IL1R2, IL1RB), Interleukin-1 receptor accessory protein (IL1RAP, IL1RAcP, IL1R3), Interleukin-18 receptor 1 (IL18R1, IL18RA) , Interleukin-18 receptor accessory protein (IL18RAP, IL18RB), Interleukin-1 receptor-like 1 (IL1RL1, ST2, IL33R), Interleukin-1 receptor-like 2 (IL1RL2, IL36R), Single Ig IL-1-related receptor (SIGIRR, TIR8), Interleukin-1 receptor accessory protein-like 1 (IL1RAPL1, TIGGIR2) and X-linked interleukin-1 receptor accessory protein-like 2 (IL1RAPL2, TIGGIR1). Most of the genes encoding these receptors are on chromosome 2.  IL1 family receptors heterodimerize upon cytokine binding. IL1, IL33 and IL36 bind specific receptors, IL1R1, IL1RL1, and IL1RL2 respectively.  All use IL1RAP as a co-receptor. IL18 binds IL18R1 and uses IL18RAP as co-receptor. The complexes formed by IL1 family cytokines and their heterodimeric receptors recruit intracellular signaling molecules, including Myeloid differentiation primary response protein MyD88 (MYD88), members of he IL1R-associated kinase (IRAK) family, and TNF receptor-associated factor 6 (TRAF6), activating Nuclear factor NF-kappa-B (NF&#954;B), as well as Mitogen-activated protein kinase 14 (MAPK14, p38), c-Jun N-terminal kinases (JNKs), extracellular signal-regulated kinases (ERKs) and other Mitogen-activated protein kinases (MAPKs).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-33 signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-33 (IL33) cytokine is a member of the Interleukin-1 family. It can be classified as an alarmin because it is released into the extracellular space during cell damage. It acts as an endogenous danger signal (Liew et al. 2010).] The gene product is biologically active (full-length IL33). Its potency has been reported to increase significantly (up to 30x) after cleavage at the N-terminus by inflammatory proteases such as Cathepsin G (CTSG) and Neutrophil elastase (ELANE) (Lefran&#231;ais et al. 2012, Lefran&#231;ais et al. 2014) but others have suggested that processing inactivates IL33 (Cayrol    Girard 2009). IL33 can act as an extracellular ligand and an intracellular signaling molecule (Martin et al. 2013, 2016). Full-length IL33 has a nuclear localization sequence and can translocate to the nucleus, where it binds heterochromatin (Moussion et al. 2008, Carriere et al. 2007, Roussel et al. 2008, Kuchler et al. 2008, Sundlisaeter et al. 2012, Baekkevold et al. 2003). IL33 that has undergone proteolytic processing is unable to translocate to the nucleus (Martin et al. 2013, Ali et al. 2010). Binding of extracellular IL33 to its receptor Interleukin-1 receptor-like 1 (IL1RL1, suppression of tumorigenicity 2, ST2) initiates several cellular signaling pathways. Cell injury or death are the dominant mechanisms by which IL33 reaches the extracellular environment, IL33 is not actively secreted by cells (Martin et al. 2016, Kaczmarek et al. 2013, Vancamelbeke et al. 2017). Because IL33 is expressed constitutively by endothelial and epithelial cells it is immediately available to the extracellular microenvironment after cell injury and necrosis (Lefran&#231;ais et al. 2012). Increases in extracellular ATP or mechanical stress correlate with increased IL33 secretion by mast cells or cardiomyocytes, respectively (Shimokawa et al. 2017, Kakkar et al. 2012, Zhao et al. 2012, Sanada et al. 2007, Chen et al. 2015).  Soluble IL1RL1 (IL1RL1 Isoform C, ST2V) (Iwahana et al. 2005, Tominaga et al. 1999) shares the extracellular components of IL1RL1, including the ligand binding domain, but lacks the transmembrane and intracellular components of IL1RL1 (Kakkar et al. 2008, Iwahana et al. 1999). The IL33-IL1RL1 complex recruits a co-receptor, most commonly IL1 receptor accessory protein (IL1RAP, IL-1RAcP) (Schmitz et al. 2005, Lingel et al. 2009, Palmer et al. 2008, Liu et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37(?-218) translocates from the cytosol to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
 <bp:stepProcess rdf:resource="#Catalysis17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37 binds  IL18R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37:IL18R1 binds SIGIRR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
 <bp:stepProcess rdf:resource="#Catalysis18" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37(?-218):p-S423,S425-SMAD3 translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL36:IL1RL2 binds IL1RAP-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL36RN, IL1F10 bind IL1RL2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37, IL37(?-218) binds IL18BP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL37:2x(CASP1(120-197):CASP1(317-404)) cleaves IL37</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL36 binds IL1RL2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Caspase-1 active tetramer formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
 <bp:stepProcess rdf:resource="#Catalysis12" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 family precursors are cleaved by caspase-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p62:MEKK3 binds to TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction48" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTSG cleaves CASP1(1-404)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction53" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
 <bp:stepProcess rdf:resource="#Catalysis14" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 family are secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#Catalysis16" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of caspase-1 p10/p20 dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction46" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1 is activated within the TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction57" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hyperphosphorylated IRAK1 associates with TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction59" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hp-IRAK1,hp-IRAK4 bind Pellino1,2,3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction55" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TAK1 phosphorylates MKK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction56" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction73" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction64" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction70" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
 <bp:stepProcess rdf:resource="#Catalysis9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
 <bp:stepProcess rdf:resource="#Catalysis10" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
 <bp:stepProcess rdf:resource="#Catalysis7" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
 <bp:stepProcess rdf:resource="#Catalysis6" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B inhibitor binds NF-kappa-B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of IKBKG by TRAF6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBIP binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP18 binds IKBKG within IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCF Beta-TrCP complex binds to NFKB p50:p65: phospho IKBA complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-TrCP ubiquitinates NFKB p50:p65:phospho IKBA complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active IKBKB phosphorylates NF-kappa-B inhibitor </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRRC14 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitinated and phosphorylated IKBA binds to and is degraded by the proteasome complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction26" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 is activated by autophosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction30" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4-activated IRAK1 autophosphorylates</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction20" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">K63polyUb-IRAK1 dissociates</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction24" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 binding leads to IRAK1:TRAF6 release</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UBE2N:UBE2V1 dissociates from hp-IRAK1:3xK63-polyUb-TRAF6:3xUBE2N:UBE2V1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 receptor type 2 binds Interleukin 1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1R1 binds IL1R1 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEMO binds polyubiquitinated IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction38" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKB1:RELA translocates from the cytosol to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction43" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hp-IRAK1:3xTRAF6 binds UBE2N:UBE2V1:K63-polyUb</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction36" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction37" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Interleukin 1 receptor complex binds Tollip</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyubiquitinated TRAF6 binds the TAK1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hp-IRAK1, hp-IRAK4 4 phosphorylate Pellino-1 and 2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF6 is K63 poly-ubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction79" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK2 is phosphorylated downstream of IRAK4 following IL1 receptor activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction81" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hp-IRAK1:p-Pellino, IRAK4:p-Pellino bind UBE2N:UBE2V1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction77" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1R1:IL1:IL1RAP binds MYD88 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction78" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK1 binds to MYD88 within the IL1R complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Catalysis23" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 phosphorylates IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pellino ubiquitinates IRAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CASP8 cleaves N4BP1 at D424, D490</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 binds the IKBIP gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF-kappa-B complex is transported from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CHUK, IKBKB and IKBKG form IKK complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N4BP1 binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
 <bp:stepProcess rdf:resource="#Catalysis21" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">USP14 deubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#Catalysis20" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 stimulates IKBIP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRX1 binds CHUK:IKBKB:IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#Catalysis22" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
 <bp:stepProcess rdf:resource="#Catalysis19" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRC5 binds IKBKB and CHUK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF2,6 ubiquitinates NLRC5</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>